Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gilworth (London, United Kingdom), T. Harries (London, United Kingdom), M. Thomas (Southampton, United Kingdom), C. Corrigan ( London, United Kingdom), P. Murphy (London, United Kingdom), N. Hart (London, United Kingdom), L. Hamilton (London, United Kingdom), P. White (London, United Kingdom). Deprescribing of inhaled corticosteroids in patients with COPD with mild or moderate airflow limitation: what do patients think?. 5009

Member's Comments

No comment yet.

Related content which might interest you: Withdrawal of inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: who is suitable for a trial of withdrawal? Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no? Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 COPD: Are beliefs about inhaled medication associated with patients’ inhaler technique? Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Extrafine triple therapy in patients with asthma and persistent airflow limitation Source: Eur Respir J, 56 (3) 2000476; 10.1183/13993003.00476-2020 Year: 2020 Are COPD patients with chronic dyspnea and attending pulmonary rehabilitation treated with dual bronchodilatation or not? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Bronchodilator reversibility is associated with non-adherence to inhalers in stable asthma patients, without airflow limitation. Source: Virtual Congress 2020 – Lung function diagnostics Year: 2020 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 How persistent is ²persistent airflow limitation² in severe asthma? Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006 The effect of high dose bronchodilators on cardiac function in elderly people with severe COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002 Two-year safety of targeted lung denervation in patients with moderate to severe COPD Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Acute and chronic effects of inhaled bronchodilators in patients with 'irreversible' COPD at rest and during exercise Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The importance of early applying inhaled corticosteroids in patients with mild bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006